Drug Profile
Research programme : A2A/A2B antagonists - Rebus Holdings
Alternative Names: Adenosine receptor modulators - Lewis and Clark Pharmaceuticals; LNC-003 therapeutics -1Latest Information Update: 02 May 2023
Price :
$50
*
At a glance
- Originator Lewis and Clark Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Adenosine A2A receptor antagonists; Adenosine A2B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Haematological malignancies; Solid tumours
Most Recent Events
- 30 Sep 2022 Rebus Holdings has patents pending for LNC-003 in Europe and USA, as of September 2022
- 27 Apr 2021 Research programme : A2A/A2B antagonists - Inspyr therapeutics is available for licensing as of 27 Apr 2021. http://inspyrtherapeutics.com/
- 27 Apr 2021 Inspyr therapeutics has patents pending for A2A/A2B antagonists in USA